
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune Inc. is positioned favorably in the biopharmaceutical landscape due to the promising clinical advancements of its product candidate, pemvidutide, which has shown significant efficacy in reducing liver fat and improving liver health markers in conditions such as metabolic-associated steatohepatitis (MASH) and alcoholic liver disease (ALD). The drug's dual mechanism of action, targeting both weight loss and direct liver effects, coupled with a favorable tolerability profile compared to existing therapies, enhances its attractiveness for treating obesity and metabolic diseases. Additionally, management's insights regarding potential non-invasive regulatory endpoints suggest a streamlined path for pemvidutide's approval process, further bolstering the company's growth prospects and potential market impact.
Bears say
Altimmune Inc reported a net loss of $23.2 million in the fourth quarter of 2024, reflecting financial challenges as the company navigates clinical development hurdles. The drug candidate pemvidutide, despite demonstrating a 15.6% average body weight loss in clinical trials, faces significant risks including potential challenges in market adoption, competition, and various commercialization hurdles that could impede growth. Additionally, the broader landscape is complicated by external factors such as capital market instability, ongoing risks from COVID-19, and geopolitical disruptions, all of which contribute to a negative outlook for the company’s stock.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares